G Thomas Budd, MD Professor of Medicine Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic Foundation Cleveland, Ohio		Robert W Carlson, MD Professor of Medicine Division of Oncology and Stanford Medical Informatics Stanford University Medical Center Stanford, California
	Clifford Hudis, MD Chief, Breast Cancer Medicine Service Solid Tumor Division Memorial Sloan-Kettering Cancer Center New York, New York		Joyce O’Shaughnessy, MD Co-Director, Breast Cancer Research Program, Baylor- Charles A Sammons Cancer Center US Oncology Dallas, Texas

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-theart education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Budd — Consulting Fees: Pfizer Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Genomic Health Inc, Pfizer Inc, Sanofi-Aventis. Dr Carlson — Consulting Fees: AstraZeneca Pharmaceuticals LP. Dr Hudis — Grants/ Research Support and Honorarium: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis; Consultant: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, Genomic Health Inc, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis; Stock Shareholder: Genomic Health Inc.
Dr O’Shaughnessy — Consulting Fees: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Pfizer Inc, Sanofi-Aventis; Speakers Bureau: Abraxis Oncology, Eli Lilly and Company, Sanofi-Aventis.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Margaret Peng, Lilliam Sklaver Poltorack, PharmD and Kathryn Ault Ziel, PhD – no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP – shareholder of Amgen Inc; Terry Ann Glauser, MD, MPH – Speakers Bureau: AstraZeneca Pharmaceuticals LP, Biogen Idec, Genentech BioOncology, Sanofi-Aventis. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Biogen Idec, Genentech BioOncology, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.